Catheter-based drug-device combination products: The anti-infective 5-fluorouracil-coated central venous catheter

Drug-Device Combination Products: Delivery Technologies and Applications

Volumn , Issue , 2009, Pages 93-116

  Avelar, R ^a   Jonker, A ^a  

^a Angiotech Pharmaceuticals Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTICS; BIOFILMS; COATINGS; CONTROLLED DRUG DELIVERY; HEALTH RISKS;

5-FLUOROURACIL (5-FU); ANTINEOPLASTIC DRUGS; BACTERIAL COLONIZATION; COATING FORMULATIONS; COMBINATION PRODUCTS; HOSPITAL ACQUIRED INFECTION; IMPLANTABLE MEDICAL DEVICES; PRE-CLINICAL TESTING;

CATHETERS;

EID: 78149281276     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1533/9781845697488.2.93     Document Type: Chapter

References (56)

1. Acker T., Buchanan R., Cebula T. FDA Task Force on Antimicrobial Resistance: Key recommendations and report 2000, accessed 16 April 2009. http://www.fda.gov/oc/opacom/hottopics/anti_resist.html.
2. Adrucil Teva Parenteral Medicines, Inc. 2007, (fluorouracil injection) package insert Irvine, CA [accessed 5 May 2009]. http://www.tevausa.com/default.aspx?pageid=76.
3. Aiello A.E., Marshall B., Levy S.B., Della-Latta P., Lin S.X., Larson E. Antibacterial cleaning products and drug resistance. Emerg Infect Dis 2005, 11:1565-1570.
4. Brooks S.E., Walczak M.A., et al. Chlorhexidine resistance in antibiotic-resistant bacteria isolated from the surfaces of dispensers of soap containing chlorhexidine. Infect Control Hospital Epidemiol 2002, 23:692-695.
5. Calabresi P., Chabner B.A. Chemotherapy of neoplastic disease, The Pharmacologic Basis of Therapeutics 1990, 1227-1230. Pergamon Press, New York. 8th Edition. A.G. Gilman (Ed.).
6. Casey A.L., Mermel L.A., Nightingale P., Elliott T.S.J. Antimicrobial central venous catheters in adults: a systematic review and meta-analysis. Lancet Infect Dis 2008, 8:763-776.
7. Cdc National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1990May 1999, issued June 1999. Am J Infect Control 1999, 27:520-532.
8. Chuanchuen R., Pathanasophon P., et al. Susceptibilities to antimicrobials and disinfectants in Salmonella isolates obtained from poultry and swine in Thailand. J Vet Med Sci 2008, 70:595-601.
9. Clsi Clinical and Laboratory Standards Institute Methods CLSI M7-A7 Clinical and Laboratory Standards Institute Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard 2006, Wayne, PA. 7th Edition.
10. Cms Hospital-acquired conditions 2009, Centers for Medicare and Medicaid Services, Available from:[accessed 16 April 2009]. http://www.cms.hhs.gov/HospitalAcqCond/06_Hospital-Acquired_Conditions.asp.
11. Coello R., Charlett A., et al. Device-related sources of bacteraemia in English hospitals - opportunities for the prevention of hospital-acquired bacteraemia. J Hosp Infect 2003, 53:46-57.
12. Cohen S.S., Barner H.D. Studies on unbalanced growth in Escherichia coli. Proc Natl Acad Sci USA 1954, 40:885.
13. Cohen S.S., Flaks J.G., et al. The mode of action of 5-fuorouracil and its derivatives. Proc Natl Acad Sci USA 1958, 44:1004-1012.
14. Costerton J.W., Stewart P.S., Greenberg E.P. Bacterial biofilms: a common cause of persistent infections. Science 1999, 284(5418):1318-1322.
15. Darouiche R.O. Device-associated infections: a macroproblem that starts with microadherence. Clin Infect Dis 2001, 33:1567-1572.
16. Darouiche R.O., Berger D.H., et al. Comparison of antimicrobial impregnation with tunneling of long-term central venous catheters: a randomized controlled trial. Ann Surg 2005, 242:193-200.
17. Dickinson G.M., Bisno A.L. Infections associated with indwelling devices: concepts of pathogenesis; infections associated with intravascular devices. Antimicrob Agents Chemother 1989, 33(5):597-601.
18. Dimick J.B., Pelz R.K., et al. Increased resource use associated with catheter-related bloodstream infection in the surgical intensive care unit. Arch Surg 2001, 136:229-234.
19. Donlan R.M. Biofilms and device-associated infections. Emerg Infect Dis 2001, 7:277-281.
20. Fraenkel D., Rickard C., et al. A prospective, randomized trial of rifampicin-minocycline-coated and silver-platinum-carbon-impregnated central venous catheters. Crit Care Med 2006, 34:668-675.
21. Hanna H., Bahna P., et al. Comparative in vitro efficacies and antimicrobial durabilities of novel antimicrobial central venous catheters. Antimicrob Agents Chemother 2006, 50:3283-3288.
22. Herrmann M., Vaudaux P.E., et al. Fibronectin, fibrinogen, and laminin act as mediators of adherence of clinical staphylococcal isolates to foreign material. J Infect Dis 1988, 158(4):693-701.
23. Herrmann M., Hartleib J., et al. Interaction of von Willebrand factor with Staphylooccus aureus'. J Infect Dis 1997, 176(4):984-991.
24. Hugonnet S., Sax H., Eggimann P., Chevrolet J.-C., Pittet D. Nosocomial bloodstream infection and clinical sepsis. Emerg Infect Dis 2004, 10:76-81.
25. Idsa CMS releases problematic new list of hospital-acquired conditions 2008, Infectious Diseases Society of America, IDSAnewsJune 30, 2008. Available from:[accessed 16 April 2009]. http://newsmanager.commpartners.com/idsa/issues/2008-06-30/8.html.
26. James G.A., Fisher S., Rosebrough S.F. Prevention of Staphylococcal aureus biofilm in vitro using 5-FU-coated central venous catheters 2008, Presentation #C-190.
27. Klevens R.M., Edwards J.R., Richards C.L., Horan T.C., Gaynes R.P., Pollock D.A., Cardo D.M. Estimating health care-associated infections and deaths in U.S. hospitals, 2002. Public Health Reports 2007, 122:160-166.
28. Landsdown A., Williams A. Bacterial resistance to silver in wound care and medical devices. J Wound Care 2007, 16:15-19.
29. Lorente L., Henry C., Martin M.M., JiméNez A., Mora M.L. Central venous catheter-related infection in a prospective and observational study of 2,595 catheters. Crit Care 2005, 9:R631-RR635.
30. Maki D.G., Weise C.E., Sarafin H.W. A semi-quantitative culture method for identifying intravenous-catheter-related infection. New Eng J Med 1977, 296:1305-1309.
31. Maki D.G., Stolz S., Wheeler S., Mermel L.A. A prospective, randomized trial of gauze and two polyurethane dressing for site care of pulmonary artery catheters: implications for catheter management. Crit Care Med 1994, 22:1729-1737.
32. Maki D.G., Stolz S., Wheeler S., Mermel L.A. Prevention of central venous catheter-related bloodstream infection by use of an antiseptic-impregnated catheter. A randomized, controlled trial. Ann Intern Med 1997, 127:257-266.
33. Marschall J., Mermel L.A., et al. Strategies to prevent central line-associated infections in acute care hospitals. Infect Control Hosp Epidemiol 2008, 29(Suppl 1):S22-S30.
34. Mcdonnell G., Russell A.D. Antiseptics and disinfectants: Activity, action, and resistance. Clin Microbiol Rev 1999, 12:147-179.
35. Mermel L.A. Prevention of intravascular catheter-related infections. Ann Intern Med 2000, 132(5):391-402. Erratum: Mermel, L A (2000), Ann Intern Med, 133: 395.
36. Mermel L.A., Mccormick R.D., Springman S.R., Maki D.G. The pathogenesis and epidemiology of catheter-related infection with pulmonary artery Swan-Ganz catheters: a prospective study utilizing molecular subtyping. Am J Med 1991, 91:197S-205S.
37. Centers for Disease Control and Prevention Guidelines for the prevention of intravascular catheter-related infections. Morbidity and Mortality Weekly Report 2002, 51(No. RR-10):1-30.
38. Physician'S Desk Reference Carac (fluorouracil) cream, 0.5% 2005, Thomson PDR Publishing, Montvale, NJ.
39. Pratt R.J., Pellowe C.M., Wilson J.A., Loveday H.P., Harper P.J., et al. epic2: National evidence-based guidelines for preventing healthcare-associated infections in NHS hospitals in England. J Hosp Infect 2007, 65S:S1-S64.
40. Raad I., Costerton W., et al. Ultrastructural analysis of indwelling vascular catheters: a quantitative relationship between luminal colonization and duration of placement. J Infect Dis 1993, 15:13-20.
41. Raad I., Hanna H., Maki D. Intravascular catheter-related infections: advances in diagnosis, prevention, and management. Lancet Infect Dis 2007, 7:645-657.
42. Ramritu P., Halton K., et al. A systematic review comparing the relative effectiveness of antimicrobial-coated catheters in intensive care units. Am J Infect Control 2008, 36(2):104-117.
43. Rello J., Ochagavia A., et al. Evaluation of outcome of intravenous catheter-related infections in critically ill patients. Am J Resp Crit Care Med 2000, 162:1027-1030.
44. Rijnders B., Van Wijngaerden E., Peetermans W.E. Catheter-tip colonization as a surrogate end point in clinical studies on catheter-related bloodstream infection: how strong is the evidence. Clin Infect Dis 2002, 35:1053-1058.
45. Rosebrough S.F., Chamberlain A. Local tissue and intravascular safety evaluation of a 5-fluorouracil coated central venous catheter in a goat model 2008, Presentation #K-33989.
46. Sampath L.A., Tambe S.M., Modak S.M. In vitro and in vivo efficacy of catheters impregnated with antiseptics or antibiotics: evaluation of the risk of bacterial resistance to the antimicrobials in the catheters. Infect Control Hosp Epidemiol 2001, 22:640-646.
47. Shlaes D.M., Gerding D.N., John J.F., Craig W.A., Bornstein D.L., et al. SHEA position paper. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: Guidelines for the Prevention of Antimicrobial Resistance in Hospitals. Infect Control Hosp Epidemiol 1997, 18(4):275-291.
48. Healthcare Infection Control Practices Advisory Committee Management of multidrug-resistant organisms in healthcare settings, 2006. Am J Infect Control 2007, 35(10 Suppl 2):S165-S193.
49. Suller M.T.E., Russell A.D. Antibiotic and biocide resistance in methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus. J Hosp Infect 1999, 43:281-291.
50. Thomas L., Maillard J.Y., et al. Development of resistance to chlorhexidine diacetate in Pseudomonas aeruginosa and the effect of aresidualŤ concentration. J Hosp Infect 2000, 46:297-303.
51. Trautner B., Darouiche R.O. Catheter-associated infections: Pathogenesis affects prevention. Arch Intern Med 2004, 164:842-850.
52. Food U.S., Administration Drug Facts about antibiotic resistance 2009, accessed 16 April 2009. http://www.fda.gov/oc/opacom/hottopics/antiresist_facts.html.
53. Van Der Kooi T.I., De Boer A.S., et al. Incidence and risk factors of device-associated infections and associated mortality at the intensive care in the Dutch surveillance system. Intensive Care Med 2007, 33:271-278.
54. Von Eiff C., Jansen B., Kohnen W., Becker K. Infections associated with medical devices: pathogenesis, management, and prophylaxis. Drugs 2005, 65(2):179-214.
55. Walz J.M., Fontecchio S., Heard S.O. Use of catheters impregnated with minocycline and rifampine and the risk of fungemia. Crit Care Med 2001, 29:A109.
56. Walz J.M., Luber J., Reyno J., Stanford G., Gitter R., Longtine K.J., Longtine J.K., O'Neill M.A., Heard S.O. A multicenter randomized controlled clinical trial comparing central venous catheters impregnated with either 5-fluorouracil or chlorhexidine/silver sulfadiazine in preventing catheter colonization. Crit Care 2008, 12(Suppl 2):P40.